XML 44 R34.htm IDEA: XBRL DOCUMENT v3.25.3
Shareholders' Equity (Tables)
9 Months Ended
Sep. 30, 2025
Equity [Abstract]  
Schedule of the Stock Option and RSU Award Activities
The following table summarizes the stock option and Restricted Share Unit ("RSU") award activities under the Company's share-based compensation plans for the nine months ended September 30, 2025:
Shares Subject to Options OutstandingOutstanding RSUs
Number of Options(1)
Weighted Average Exercise PriceRemaining Contractual Term (in years)
Aggregate Intrinsic Value(2)
Weighted Average Grant Date Fair ValueOutstanding RSUsWeighted Average Grant Date Fair Value
(in US $ millions, except share and share price amounts)
December 31, 202414,636,992 64.497.68623  5,121,069 74.90 
Stock options granted1,622,585 122.59— — 63.66 — — 
Stock options exercised(3,029,467)41.77— — — — — 
Stock options forfeited(1,306,389)78.53— — — — — 
RSUs granted— — — — 3,000,370 115.21 
RSUs settled— — — — (3,419,188)82.36 
RSUs forfeited— — — — (817,552)77.37 
September 30, 202511,923,721 76.637.03826  3,884,699 98.95 
Stock options exercisable as of September 30, 2025
6,072,409 68.295.52479 
(1) As of September 30, 2025, 11,886,690 of the outstanding stock options were granted under the Company's SOP and are exercisable for Class A subordinate voting shares and 37,031 of the outstanding stock options were granted under the Deliverr 2017 Stock Option and Grant Plan and are exercisable for Class A subordinate voting shares.
(2) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock option awards and the closing market price of the Company's Class A subordinate voting shares as of September 30, 2025 and December 31, 2024.
Schedule of Classification of Stock-based Compensation
The following table illustrates the classification of stock-based compensation expense in the condensed consolidated statements of operations and comprehensive income, which includes both stock-based compensation and restricted stock-compensation expense:
Three months ended September 30,Nine months ended September 30,
2025202420252024
(in US $ millions)
Cost of revenues134
Sales and marketing12143535
Research and development7374232212
General and administrative21226470
107110334321